KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

KALV EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

KalVista Pharmaceuticals, Inc.NASDAQ: KALV

EBITDA · Q4 FY2026 · quarter ended Dec 2025

EBITDA of -$17.55M in Q4 FY2026

Q4 FY2026 EBITDA was -$17.55M. Trailing-twelve-month EBITDA was -$117.15M.

Context

  • EBITDA amounted to 204.6% of revenue in FY2026.
  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of $119.43M (+179.3%) for the fiscal year ending Dec 2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$17.55M+58.4% QoQ
Last fiscal yearDec 2025
-$150.62M— YoY
LTMDec 2025
-$117.15M— YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year—+179.3%—
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2026
(150.62M) USD
Year-over-year change
+13.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How KALV compares with its peers on the latest reported figures

  • KALV's LTM Dec 2025 EBITDA of -$117.15M is the 5th highest of the 10 companies compared; the peer median is -$163.43M.
  • EBITDA amounts to 101.1% of revenue for KALV, versus a peer median of 244.6%.
KALV Competitors Peer median
EBITDA for KALV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$131.28M +170.9%—43.8%
OMEROmeros CorporationLTM Mar 2026$92.9M +159.9%—939.0%
PRTAProthena Corporation plcLTM Mar 2026-$74.72M +35.0%—129.0%
ADCTADC Therapeutics S.A.LTM Mar 2026-$83.2M +13.7%—105.1%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-$117.15M ——101.1%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$163.43M +3.9%—185.2%
GOSSGossamer Bio, Inc.LTM Mar 2026-$168.81M -372.8%—304.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$184.67M -43.8%——
VSTMVerastem, Inc.LTM Mar 2026-$191.95M -32.3%—387.1%
BCYCBicycle Therapeutics plcLTM Mar 2026-$211.5M -0.8%—333.1%
Peer median (excluding KALV) -$163.43M+3.9%—244.6%

Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Revenue000073.62M
Cost of Revenue0086.17M06.08M
Gross Profit00(86.17M)067.54M
Gross Margin————91.7%
Research & Development70.17M80.28M86.17M71.71M55.64M
Selling, General & Admin26.45M30.6M54.28M116.29M183.74M
Operating Expenses96.61M110.87M54.28M188M239.38M
Depreciation & Amortization564K718K816K941K1.45M
EBITDA(80.75M)(94.37M)(134.28M)(173.33M)(150.62M)
EBITDA Margin————-204.6%
Operating Income(96.61M)(110.87M)(140.45M)(188M)(171.84M)
Operating Margin————-233.4%
Interest Income1.09M2.23M3.9M6.44M8.68M
Interest Expense0005.79M19.34M
Other Income / Expenses14.27M17.96M5.35M7.94M420K
Income Before Tax(82.34M)(92.91M)(135.1M)(180.05M)(171.42M)
Pre-Tax Margin————-232.9%
Income Tax Expense00(8.45M)3.39M(7.13M)
Net Income(82.34M)(92.91M)(126.64M)(183.44M)(164.29M)
Net Margin————-223.2%
EPS (Basic)(3.36)(3.33)(3.44)(3.69)(3.23)
EPS (Diluted)(3.36)(3.33)(3.44)(3.69)(3.23)
Weighted Avg Shares24.47M27.89M36.79M49.65M50.9M
Weighted Avg Shares (Diluted)24.47M27.89M36.79M49.65M50.9M

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Intrinsic Alpha fair value

Locked

Current Price

$27.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.